HeHealth, an AI-enabled healthcare solution platform for penis health, launches its mobile-first application in Singapore. This marks the country’s first penis-focused STD (Sexually Transmitted Diseases) detection app.
HeHealth features a fully built penis-checking AI tool that allows you to get instant results anonymously for your STD concerns through a digital image. Operating in live testing for 18 months before its official launch on Google and Apple stores in April 2022, HeHealth has run over 1000 AI analyses for with results that have also been verified by doctors as of July 2022 since the app launch.
In just a few clicks on the app and through the power of HeHealth’s customised convolutional neural network AI model, the platform solution can detect an STD almost instantly and discreetly through a digital image.
The first-of-its-kind technology can not only recognise STDs but also other types of rare penile conditions like penile cancer. From early research, HeHealth’s AI outperforms primary care physicians in some more challenging disease cases and has an accuracy rate of 90% for HPV screening.
All this while prioritising anonymity, HeHealth does not collect any form of user’s personal information.
The solution regularly advises you to comply with their multi-layer privacy and security measures such as refraining from using real names or main email addresses on their accounts.
Further lowering the barrier to STD screening, HeHealth is also currently free-of-charge.
Early detection is key when it comes to managing all STDs. The World Health Organisation has estimated that more than 1 million STDs are acquired every day. STDs can have serious consequences beyond the immediate impact of the infection itself, including infertility, cancer, increased risk of HIV acquisition, and many other health consequences if the infections are left untreated.
HeHealth is part of the SMU BIG Incubator program and is working with the National University Singapore (NUS) research committee to conduct research to help improve the accuracy and further develop the AI of the platform.
HeHealth is currently awaiting approvals from the Health Science Authority in Singapore and NUS to commence their stage 2 of clinical trials which reviews and monitors biomedical research that HeHealth is doing to further support the science behind its product. Most recently, HeHealth was shortlisted by the fastest growing tech conference in North America, Collision 2022, as one of the many Impact Start-ups and was invited to participate in the conference in Toronto.
Currently, HeHealth is also working towards launching a telehealth service which will cover all facets of the care pathway, from screening, consultation, testing, and treatment. More information about this will be released later in the year.